If you have hypothyroidism or hyperthyroidism, ensure these conditions are well-controlled before starting GLP-1 therapy
Large BMJ Study Confirms GLP-1 Drugs Like Ozempic and Mounjaro Are Linked to a Real Hair Loss Risk A large peer-reviewed study published in the British Medical Journal on July 22, 2026, has found that adults using GLP-1 receptor agonist drugs including semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) had a significantly higher rate of clinically recorded hair loss compared with people taking two other commonly prescribed diabetes medications
Though clinical trials are delivering optimistic outcomes, FDA submission is pending, with projections not indicating a release date until possibly 2028
This portends the synergistic activation of the pathway when both drugs are used together
MCCPDC has the potential to infuse serious capital into correcting the market failure of generic drug shortages
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Recently, studies have suggested a potential link between drugs like Ozempic (semaglutide) and a rare but serious condition called non-arteritic anterior ischemic optic neuropathy (NAION)
